JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY 499.00
+6.00 (1.22%)
Nov 13, 2026, 3:25 PM JST
JCR Pharmaceuticals Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 38,931 | 40,319 | 33,072 | 42,871 | 34,343 | 51,082 | |
Revenue Growth | 3.06% | 21.91% | -22.86% | 24.83% | -32.77% | 69.79% |
Cost of Revenue | 11,613 | 10,134 | 10,902 | 11,620 | 8,886 | 10,461 |
Gross Profit | 27,318 | 30,185 | 22,170 | 31,251 | 25,457 | 40,621 |
Selling, General & Admin | 32,696 | 12,868 | 12,958 | 12,485 | 11,678 | 13,511 |
Research & Development | - | 16,761 | 15,431 | 11,234 | 8,802 | 7,175 |
Operating Expenses | 32,821 | 29,754 | 28,580 | 23,719 | 20,480 | 20,686 |
Operating Income | -5,503 | 431 | -6,410 | 7,532 | 4,977 | 19,935 |
Interest Expense | -578 | -398 | -155 | -86 | -44 | -45 |
Interest & Investment Income | 106 | 119 | 147 | 137 | 61 | 35 |
Earnings From Equity Investments | -187 | -184 | -467 | -1,090 | - | - |
Currency Exchange Gain (Loss) | 506 | 706 | -196 | 767 | 387 | 551 |
Other Non Operating Income (Expenses) | 192 | 33 | 35 | 2 | 56 | 35 |
EBT Excluding Unusual Items | -5,464 | 707 | -7,046 | 7,262 | 5,437 | 20,511 |
Gain (Loss) on Sale of Investments | 416 | 666 | - | - | 10 | - |
Gain (Loss) on Sale of Assets | -11 | -32 | -2 | -20 | -36 | -2 |
Other Unusual Items | 1,882 | 1,882 | 1,065 | - | - | -1,106 |
Pretax Income | -3,177 | 3,223 | -5,983 | 7,242 | 5,411 | 19,403 |
Income Tax Expense | 236 | 1,017 | -1,586 | 1,707 | 1,625 | 4,886 |
Earnings From Continuing Operations | -3,413 | 2,206 | -4,397 | 5,535 | 3,786 | 14,517 |
Minority Interest in Earnings | -22 | -28 | -63 | -28 | -14 | -10 |
Net Income | -3,435 | 2,178 | -4,460 | 5,507 | 3,772 | 14,507 |
Net Income to Common | -3,435 | 2,178 | -4,460 | 5,507 | 3,772 | 14,507 |
Net Income Growth | - | - | - | 46.00% | -74.00% | 110.49% |
Shares Outstanding (Basic) | 122 | 122 | 124 | 125 | 124 | 124 |
Shares Outstanding (Diluted) | 122 | 122 | 124 | 125 | 125 | 124 |
Shares Change | -0.18% | -1.47% | -1.25% | 0.45% | 0.51% | 0.06% |
EPS (Basic) | -28.14 | 17.86 | -36.02 | 44.13 | 30.34 | 117.26 |
EPS (Diluted) | -28.14 | 17.86 | -36.02 | 43.92 | 30.22 | 116.80 |
EPS Growth | - | - | - | 45.33% | -74.13% | 110.34% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -24,589 | -11,562 | -15,373 | 7,786 | -13,154 | -2,044 |
Free Cash Flow Per Share | -201.47 | -94.76 | -124.15 | 62.09 | -105.37 | -16.46 |
Dividend Per Share | 20.000 | 20.000 | 20.000 | 20.000 | 20.000 | 20.000 |
Dividend Growth | 0% | 0% | 0% | 0% | 0% | 73.91% |
Gross Margin | 70.17% | 74.87% | 67.04% | 72.89% | 74.13% | 79.52% |
Operating Margin | -14.13% | 1.07% | -19.38% | 17.57% | 14.49% | 39.02% |
Profit Margin | -8.82% | 5.40% | -13.49% | 12.85% | 10.98% | 28.40% |
Free Cash Flow Margin | -63.16% | -28.68% | -46.48% | 18.16% | -38.30% | -4.00% |
EBITDA | -3,324 | 2,988 | -3,036 | 10,729 | 6,974 | 21,880 |
EBITDA Margin | -8.54% | 7.41% | -9.18% | 25.03% | 20.31% | 42.83% |
D&A For EBITDA | 2,179 | 2,557 | 3,374 | 3,197 | 1,997 | 1,945 |
EBIT | -5,503 | 431 | -6,410 | 7,532 | 4,977 | 19,935 |
EBIT Margin | -14.13% | 1.07% | -19.38% | 17.57% | 14.49% | 39.02% |
Effective Tax Rate | - | 31.55% | - | 23.57% | 30.03% | 25.18% |